|
1
|
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
|
Clin Cancer Res
|
2002
|
4.90
|
|
2
|
Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.
|
Clin Cancer Res
|
2012
|
3.35
|
|
3
|
Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.
|
Drug Resist Updat
|
2012
|
1.23
|
|
4
|
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
|
Clin Cancer Res
|
2012
|
1.09
|
|
5
|
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection.
|
J Immunol
|
2008
|
1.04
|
|
6
|
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
|
Endocr Relat Cancer
|
2011
|
0.91
|
|
7
|
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor.
|
Chemother Res Pract
|
2010
|
0.86
|
|
8
|
Radiofrequency ablation of metastatic pheochromocytoma.
|
J Vasc Interv Radiol
|
2009
|
0.82
|
|
9
|
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?
|
Oncologist
|
2013
|
0.76
|
|
10
|
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
|
J Clin Invest
|
2016
|
0.75
|
|
11
|
Clinical trial results: Sharing results, speeding discoveries.
|
Oncologist
|
2013
|
0.75
|